Paget's disease of bone

Human medicines European public assessment report (EPAR): Aclasta, zoledronic acid, Date of authorisation: 15/04/2005, Revision: 32, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, INN, Risk, Woman, Hypercalcaemia, Menopause, Man, Cancer, Avascular necrosis, Risk management, Anatomy, Female, IIA, Osteitis, Jaw, Osteoclast, CHMP, Fever, Fracture, ATC, Pain, European, Disease, Calcium, Kidney, Paget's disease, Glucocorticoid, Neoplasm, Arthralgia, Hypocalcemia, Patient, Medical Subject Headings, Hip, Trauma, European Commission, Vitamin D, International, Language, Mouth, Select, Medicine, Paget's disease of bone, Allergy, Headache, Ibuprofen, Spine, Myalgia, Committee, Cell, Necrosis, Dietary supplement

Human medicines European public assessment report (EPAR): Aclasta, zoledronic acid, Date of authorisation: 15/04/2005, Revision: 32, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Aclasta, zoledronic acid, Date of authorisation: 15/04/2005, Revision: 32, Status: Authorised

Global Bone Cancer Markets, Epidemiology and Patient Flow Report 2020-2035 - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 13, 2021
Pharmaceutical, Health, Oncology, Musculoskeletal system, Carcinogenesis, Epidemiology of cancer, Branches of biology, Medication-related osteonecrosis of the jaw, Bone, Cancer, Paget's disease of bone

b'The "Global Bone Cancer Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Bone Cancer Epidemiology and Patient Flow Analysis - 2021, provides Bone Cancer epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Bone Cancer Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Bone Cancer Epidemiology and Patient Flow Analysis - 2021, provides Bone Cancer epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Bone Cancer patients, history of the disease at the population level (Bone Cancer prevalence, Bone Cancer incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Bone Cancer patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Bone Cancer market sizing, assessing market potential, and developing drug forecast models\nIdentify Bone Cancer patients segments through age groups, gender, and disease sub-types\nEvaluate Bone Cancer market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210513005624/en/\n'

Trivedi Global, Inc. Announces Research by Dahryn Trivedi on the Impact of the Trivedi Effect to Significantly Improve Bone Health

Retrieved on: 
Friday, July 5, 2019
Musculoskeletal system, Organ systems, Osteopathies, Anatomy, Bone, Paget's disease of bone, Osteoporosis, Medication related osteonecrosis of the jaw, Osteoma, Pathologic fracture

The research shows over 42% increase in ALP levels, a bone specific enzyme, a useful biochemical market of bone formation which is also important for bone mineralization.

Key Points: 
  • The research shows over 42% increase in ALP levels, a bone specific enzyme, a useful biochemical market of bone formation which is also important for bone mineralization.
  • The results suggests the potential benefits of the Trivedi Effect in impacting numerous bone-related disorders viz.
  • rickets, osteoporosis, deformed bones, Paget's disease of bone, bone loss and fractures, bone and/or joint pain, and osteoma.
  • Dahryn Trivedi provided this Biofield Energy Healing Treatment remotely from the United States, while the test samples were in the research laboratory of Dabur Research Foundation, near New Delhi, India.

Scaffolds Seeded With Molecule-Releasing Stem Cells Shows Promise In Treating Fatal Bone Disease

Retrieved on: 
Wednesday, September 5, 2018
Skeletal system, Anatomy, Zoology, Biology, Bone, Osteoclast, Osteochondritis dissecans, Paget's disease of bone, Osteopetrosis

The findings, recently published in STEM CELLS Translational Medicine (SCTM), might someday yield a treatment for humans afflicted by the same devastating condition.

Key Points: 
  • The findings, recently published in STEM CELLS Translational Medicine (SCTM), might someday yield a treatment for humans afflicted by the same devastating condition.
  • Osteoclasts break down bone tissue during bone remodeling, a normal process in which old or damaged bone is removed and new bone is produced to replace it.
  • In ARO the osteoclasts fail to resorb bone, leading to restriction of bone marrow cavity and cranial nerve spaces.
  • People with ARO have a high risk of bone fracture from minor bumps and falls or for no apparent reason.